Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Clinical Trials

Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile

Phase 4

Completed

Conditions: Coronary Artery Disease (CAD)

Interventions: Drug: Clopidogrel
Drug: Ticagrelor

First Posted Date: 2022-08-26

Last Posted Date: 2022-09-01

Lead Sponsor: Universiti Sains Malaysia

Target Recruit Count: 80

Registration Number: NCT05516784

Locations: 🇲🇾
Department of Cardiology, Penang General Hospital, George Town, Penang, Malaysia

Aspirin vs Clopidogrel After TAVR

Not Applicable

Recruiting

Conditions: Severe Aortic Stenosis

Interventions: Drug: Aspirin single antiplatelet therapy
Drug: Clopidogrel single antiplatelet therapy

First Posted Date: 2022-08-09

Last Posted Date: 2024-10-14

Lead Sponsor: Yonsei University

Target Recruit Count: 230

Registration Number: NCT05493657

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA

Completed

Conditions: TIA
Ischemic Stroke

Interventions: Drug: Aspirin
Drug: Clopidogrel
Drug: Ticagrelor

First Posted Date: 2022-07-27

Last Posted Date: 2024-12-05

Lead Sponsor: University of L'Aquila

Target Recruit Count: 2239

Registration Number: NCT05476081

Locations: 🇮🇹
Neurology e Stroke Unit Departement, SS Filippo e Nicola Hospital, Avezzano, Abruzzo, Italy
🇮🇹
Department of Neurology and Stroke Unit, Ente Ecclesiastico ospedale Generale Regionale Miulli, Acquaviva Delle Fonti, Italy
🇮🇹
Department of Neurology, Murgia Hospital Fabio Perinei SS 96, Altamura, Italy

and more 124 locations

A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke

Phase 4

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: Plavix 75mg
Drug: Renexin CR 200/160mg

First Posted Date: 2022-07-06

Last Posted Date: 2023-01-04

Lead Sponsor: SK Chemicals Co., Ltd.

Target Recruit Count: 500

Registration Number: NCT05445895

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Low Dose Prasugrel vs Clopidogrel for Stenting or Flow Diverter for Unruptured Aneurysm

Phase 4

Recruiting

Conditions: Intracranial Aneurysm

Interventions: Drug: Clopidogrel group
Drug: Prasugrel group

First Posted Date: 2022-05-03

Last Posted Date: 2022-07-15

Lead Sponsor: Yonsei University

Target Recruit Count: 406

Registration Number: NCT05359224

Locations: 🇰🇷
Yongin Severance hospital, Yonsei university college of medicine, Gyeonggi-do, Yongin-si, Korea, Republic of

Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Onyx Stents Implantation; C-MODE Trial

Not Applicable

Recruiting

Conditions: Ischemic Heart Disease

Interventions: Drug: Clopidogrel monotherapy
Drug: Aspirin monotherapy
Device: zotarolimus-eluting stent (Resolute Onyx ®)

First Posted Date: 2022-04-11

Last Posted Date: 2024-10-22

Lead Sponsor: Yonsei University

Target Recruit Count: 3744

Registration Number: NCT05320926

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Optimal Duration of Dual Antiplatelet Therapy After Stent-assisted Coiling

Phase 4

Active, not recruiting

Conditions: Endovascular Procedures
Aneurysm Cerebral

Interventions: Drug: Aspirin 100mg
Drug: Clopidogrel 75mg

First Posted Date: 2022-02-25

Last Posted Date: 2025-05-16

Lead Sponsor: Seoul National University Bundang Hospital

Target Recruit Count: 528

Registration Number: NCT05257824

Locations: 🇰🇷
Chungnam National University Sejong Hospital, Sejong, Chungcheongnam-do, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Pusan National University Yangsan Hospital, Yangsan, Gyeongsangnam-do, Korea, Republic of

and more 5 locations